BioXcel Therapeutics (BTAI) announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market that the Company has regained compliance with the market value of listed securities, MVLS, requirement under Nasdaq Listing Rule 5550(b)(2). On September 17, 2025, Nasdaq delivered a notice to the Company confirming it had regained compliance with the MVLS Rule. The Company now meets all Nasdaq Capital Market listing requirements for continued listing and this matter is now closed.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- Bioxcel Therapeutics Files Current Report on Form 8-K
- BioXcel Therapeutics says has raised $37.3M since July 1 under ATM offering
- BioXcel Therapeutics completes enrollment in clinical study
- Promising Phase 3 Trial Results and Growth Potential for Bioxcel Therapeutics’ BXCL501 Reinforce Buy Rating
- BioXcel Therapeutics price target raised to $4 from $2 at Mizuho